Should The NICE Cost-Effectiveness Range Be Lowered?

This question goes to the heart of the use of the cost per quality-adjusted life-year (QALY) in healthcare decision making. Download or View Article here. (Source: J.P. Raftery, University of Southhampton, 5/9/14).

You might also be interested in:

CVS Caremark's Foray into Cost-Effectiveness Analysis Raises… September 25, 2018
ICER Report: HAE Treatments Yield Health Improvements, but at… October 14, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
CVS Caremark Pushes Forward with QALYs Despite Patient Groups'… December 3, 2018
Opinion: Abandon QALY Metric in Cost-Effectiveness Reviews February 22, 2019
ISPOR 2019 Panel Spotlights QALY Metric May 22, 2019
PhRMA Offers Recommendations for ICER's Value Assessment Framework June 21, 2019